STAT's Adam Feuerstein took a shot at ImmunoCellular Therapeutics (NYSE: IMUC) on twitter after ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Momentum Movers Short Sales Trader Talk

ImmunoCellular Therapeutics (IMUC) Says it Achieved Key Milestone in Stem-to-T-Cell Research Immuno-Oncology ProgramDecember 13, 2017 4:19 PM ImmunoCellular Therapeutics Achieves Key Milestone in Stem-to-T-Cell Research Immuno-Oncology ProgramDecember 13, 2017 4:05 PM